viewSensyne Health PLC

Sensyne Health PLC - Sensyne Health Agreement with Somerset NHS Trust

RNS Number : 3521F
Sensyne Health PLC
16 November 2020

Sensyne Health and Somerset NHS Foundation Trust

sign Strategic Research Agreement


Non-exclusive agreement covers a total of 1.1 million anonymised patient records and brings total number of records available to Sensyne for research to over 5.6 million


Enables the ethical application of clinical artificial intelligence research on anonymised patient data to improve patient care and accelerate research into new medicines


Somerset NHS Foundation Trust receives equity stake in Sensyne Health plc and will receive IT research funding and a share of revenues



Oxford, U.K. 16 November 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces that it has signed a five year non-exclusive Strategic Research Agreement (SRA) with Somerset NHS Foundation Trust ("Somerset" or "The Trust"). 


The agreement will enable the ethical application of clinical AI research to improve patient care and accelerate research into new medicines. The Somerset dataset covers 1.1 million unique patient records from a patient population of approximately 600,000 people.

Somerset NHS Foundation Trust is the first NHS trust on the English mainland to provide community, mental health and acute hospital services. The Trust was formed on 1 April 2020 when Somerset Partnership NHS Foundation Trust and Taunton and Somerset NHS Foundation Trust merged. It employs over 9,000 colleagues and provides community and mental health services across the whole of Somerset and acute hospital services in the north, west and centre of the county and beyond. 

Research under this SRA will be undertaken to the highest standards of information governance and data security in accordance with NHS principles, the UK Government Code of Practice and data protection legislation. All data supplied to Sensyne will be anonymised by Somerset beforehand and the provision of the data will operate under an agreed Data Processing Protocol ("DPP") under the Trust's ethical oversight. 


Somerset will receive 1,428,571 ordinary shares in Sensyne Health plc representing 1.11% of the existing issued share capital of Sensyne. This will bring the total share ownership held by NHS Trusts in Sensyne to 11.7% of the share capital (as enlarged by the issue of shares to Somerset and Milton Keynes University Hospital NHS Foundation Trust). The Trust will also receive from Sensyne an investment of up to £250,000 per year over the five-year term of the contract for specific investments in information technology to enable the curation and analysis of data under the SRA. The Trust will also receive a royalty on revenues that are generated by Sensyne from the research undertaken under the SRA. The financial return Somerset receives from Sensyne will be reinvested back into the NHS to fund patient care. The Trust has entered into a lock-up agreement whereby it has agreed not to dispose of any shares for a period of two years from the date the shares are issued.


Somerset joins six existing SRAs that the Company has in place with Oxford University Hospitals NHS Foundation Trust, Chelsea & Westminster Hospitals NHS Foundation Trust, South Warwickshire NHS Foundation Trust, Wye Valley NHS Trust, George Eliot NHS Trust, Milton Keynes University Hospital NHS Foundation Trust[1] and a data access agreement signed with NHS Greater Glasgow and Clyde.

This new SRA with the Somerset NHS Trust brings the combined total of anonymised patient data available for analysis by Sensyne to 5.6 million patients, exceeding its 5 million target set at IPO in August 2018.


David Shannon, Director of Strategic Development and Improvement for Somerset Partnership NHS Foundation Trust, said:

"We are very pleased to reach this exciting and innovative partnership with Sensyne. Our organisation is committed to delivering outstanding care by continually listening, learning and improving and believe this partnership has the potential to help us improve care further and contribute to improvements in care  across the country."


Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"We are delighted to be working with Somerset NHS Foundation Trust.  This new agreement will enable research to improve patient care and accelerate medical research and by helping to grow our overall data set to over 5.6m patients, will now enable us to broaden our research and expand our therapeutic focus."


The issue of new ordinary shares in Sensyne Health to the Somerset Partnership NHS Foundation Trust remains subject to receipt of a s593 report by the Company and a further announcement will be made in due course once the shares have been issued and allotted.








For more information please contact:

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer


Michael Norris, Interim Chief Financial Officer



Peel Hunt LLP (Nominated Adviser and Joint Broker)


+ 44 (0) 20 7418 8900

Dr Christopher Golden


James Steel


Oliver Jackson


Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma


Euan Brown


Consilium Strategic Communications

+44 (0) 77 0286 8207

Mary-Jane Elliott


Sukaina Virji


Melissa Gardiner






About Sensyne Health 


Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).


For more information, please visit: www.sensynehealth.com




[1] The SRAs with George Eliot & Wye Valley remain subject to NHS England approval prior to final closing and issue of shares in Sensyne. 



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: Sensyne Health PLC

Price: 157.5

Market: AIM
Market Cap: £250.56 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Sensyne Health launch first digital health product in the U.S for diabetes...

Sensyne Health's CEO (LON:SENS) Lord Paul Drayson talks to Proactive London about their first digital health product in the U.S that can remotely monitor for diabetes in pregnancy. The group's partner Cognizant will oversee the roll-out of GDm-Health across the Atlantic. Drayson talks...

on 15/12/20